Zidovudine use during pregnancy among HIV-infected women on medicaid

Journal of Acquired Immune Deficiency Syndromes

Volumn 30, Issue 4, 2002, Pages 429-439

  Sambamoorthi, Usha ^a   Akincigil, Ayse ^a   McSpiritt, Elizabeth ^a   Crystal, Stephen ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

AIDS HIV; Medicaid; Pregnancy; Prenatal care; Zidovudine

Indexed keywords

ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DELIVERY; DRUG USE; ETHNOLOGY; FEMALE; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MEDICAID; MEDICAL CARE; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; PRENATAL CARE; PRIORITY JOURNAL; PROPHYLAXIS;

EID: 0036682592     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200208010-00009     Document Type: Article

References (55)

1. Zidovudine for the prevention of HIV transmission from mother to infant
2. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
3. After AIDS clinical trial 076: The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants
4. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties
5. Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV. Perinatal AIDS Collaborative Transmission Studies
6. Reduction in the risk of Vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone
7. Trends in perinatal transmission of HIV/AIDS in the United States
8. The mode of delivery and the risk of vertical transmission of HIV type 1
9. HIV/AIDS Surveillance Report
10. Can perinatal HIV infection be eliminated in the United States?
11. Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center
12. Success in implementing public health service guidelines to reduce perinatal transmission of HIV - Louisiana, Michigan, New Jersey and South Carolina, 1993, 1995, and 1996
13. Trends in zidovudine prescription for pregnant women infected with HIV
14. Translating clinical trial results into practice: The effect of an AIDS clinical trial on prescribed antiretroviral therapy for HIV-infected pregnant women
15. Adequacy of prenatal care and prescription of zidovudine to prevent perinatal HIV transmission
16. Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina
17. Adherence to antiretroviral therapy by pregnant women infected with HIV: A pharmacy claims-based analysis
18. Mother-to-child transmission of the human immunodeficiency virus in Texas
19. Successful implementation of perinatal HIV prevention guidelines
20. Perinatal zidovudine use after perinatal ZDV recommendations in the United States
21. Lack of timely prenatal care among women infected with HIV: Implications for prevention of perinatal HIV transmission in the United States
22. HIV-infected women: Barriers to AZT use
23. HIV pregnancy and zidovudine: What do women know?
24. Prenatal care and HIV infection
25. Sociodemographic/behavioral characteristics and neonatal outcomes among HIV infected pregnant women and infants transmission multicenter study (WITS)
26. Constructing episodes of care from encounter and claims data: Some methodological issues
27. Prenatal care and birth outcomes of a cohort of HIV-infected women
28. Recommendations of the United States Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus
29. The diffusion of innovation in AIDS treatment: Zidovudine use in two New Jersey cohorts
30. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1
31. Brief report: Primary infection with zidovudine-resistant human immunodeficiency virus type 1
32. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
33. HIV-1 drug resistance in newly infected individuals
34. Improved birth outcomes associated with enhanced Medicaid prenatal care in drug-using women infected with the human immunodeficiency virus
35. Survey of physician's use of zidovudine in HIV-infected pregnant females and their newborn infants
36. Relation of the content of prenatal care to the risk of low birth weight. Maternal reports of health behavior advice and initial prenatal care procedures
37. Longitudinal data analysis using generalized linear models
38. Reducing the risk of maternal-infant transmission of HIV: A door is opened
39. Prevention of vertical HIV transmission with zidovudine: Projected impact of HIV testing and prenatal care
40. Pregnancy and HIV: Guidelines for your practice
41. Uptake of interventions to reduce mother-to-child transmission of HIV in the United Kingdom and Ireland
42. Comparing generalist and specialty care: Discrepancies, deficiencies, and excesses
43. Differences between generalist and specialist physicians regarding Helicobacter pylori and peptic ulcer disease
44. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction
45. Differences in generalist and specialist physicians' knowledge and use of angiotensinconverting enzyme inhibitors for congestive heart failure
46. Implications of generalists' slow adoption of zidovudine in clinical practice
47. The role of medical problems and behavioral risks in explaining patterns of prenatal care use among high-risk women
48. Adequacy of prenatal care among inner city women
49. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring
50. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy
51. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus